Targocid and associated names
- Procedure started
- Under evaluation
- CHMP opinion
- European Commission final decision
Table of contents
Current status:
European Commission final decision
Overview
On 30 May 2013, the European Medicines Agency completed a review of Targocid. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for Targocid in the European Union (EU).
Key facts
Approved name |
Targocid and associated names
|
International non-proprietary name (INN) or common name |
teicoplanin |
Associated names |
|
Class |
-
|
Reference number |
EMEA/H/A-30/1301
|
Type |
Article 30 referrals
This type of referral is triggered when Member States have adopted different decisions over the years for some medicines (e.g. different indications, contraindications or posology) and there is a need to harmonise across the EU. |
Status |
European Commission final decision
|
Opinion date |
30/05/2013
|
EC decision date |
12/09/2013
|
All documents
-
List item
Questions and answers on Targocid and associated names (teicoplanin, powder or powder and solvent for solution for injection, infusion or oral solution, 100, 200 and 400 mg) (PDF/78.52 KB)
First published: 31/05/2013
Last updated: 03/01/2014
EMA/319080/2013 -
-
List item
Targocid Article-30 referral - Annex I (PDF/281.61 KB)
First published: 03/01/2014
Last updated: 03/01/2014 -
-
List item
Targocid Article-30 referral - Annex II (PDF/146.78 KB)
First published: 03/01/2014
Last updated: 03/01/2014 -
-
List item
Targocid Article-30 referral - Annex III (PDF/642.49 KB)
First published: 31/05/2013
Last updated: 03/01/2014 -
-
List item
Targocid Article-30 referral - Annex IV (PDF/34.69 KB)
First published: 03/01/2014
Last updated: 03/01/2014 -
-
List item
Targocid Article-30 referral - CHMP assessment report (PDF/230.35 KB)
Adopted
First published: 03/01/2014
Last updated: 03/01/2014
EMEA/CHMP/269452/2008
Document description
- Questions and answers (Q&A) - easy-to-understand summary of key issues and Committee conclusions
- Summary of Opinion - contains the CHMP opinion of the referred medicine(s)
- List of the medicines affected by the referral (Annex I)
- Scientific conclusions of the Committee (Annex II)
The following two documents are sometimes available:
- Changes to the summary of product characteristics, labeling or package leaflet (also known as Annex III) - available when changes havebeen recommended by the Committee
- Conditions of the marketing authorisation (also known as Annex IV) - available when the Committee recommends measures to be takenfor the marketing authorisation(s) such as safety measures or extra studies